235 related articles for article (PubMed ID: 20573398)
1. The lower risk MDS patient at risk of rapid progression.
Mittelman M; Oster HS; Hoffman M; Neumann D
Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
[TBL] [Abstract][Full Text] [Related]
2. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
5. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
6. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
14. [Myelodysplastic syndromes].
Thol F; Heuser M; Ganser A
Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
[TBL] [Abstract][Full Text] [Related]
15. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
16. Treatment of low-risk myelodysplastic syndromes.
Santini V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):462-469. PubMed ID: 27913517
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
[TBL] [Abstract][Full Text] [Related]
18. Management of lower-risk myelodysplastic syndromes: the art and evidence.
Komrokji RS; Sekeres MA; List AF
Curr Hematol Malig Rep; 2011 Jun; 6(2):145-53. PubMed ID: 21442178
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Syed YY; Scott LJ
Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
